In 2015, about 4.3 million people had non-Hodgkin lymphoma, and 231,400 (5.4%) died.[4][5] In the United States, 2.1% of people are affected at some point in their life.[2] The most common age of diagnosis is between 65 and 75 years old.[2] The five-year survival rate in the United States is 71%.[2]
Signs and symptoms
The signs and symptoms of non-Hodgkin lymphoma vary depending upon its location within the body. Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and tiredness. Other symptoms may include bone pain, chest pain, or itchiness. Some forms are slow growing, while others are fast growing.[1] Enlarged lymph nodes may cause lumps to be felt under the skin when they are close to the surface of the body. Lymphomas in the skin may also result in lumps, which are commonly itchy, red, or purple. Lymphomas in the brain can cause weakness, seizures, problems with thinking, and personality changes.[9]
While an association between non-Hodgkin lymphoma and endometriosis has been described,[10] these associations are tentative.[11]
Diagnosis
Tests for non-Hodgkin lymphoma include;
Complete blood count (CBC).
Blood chemistry studies.
Hepatitis B and hepatitis C test.
HIV test.
CT scan (CAT scan).
PET scan (positron emission tomography scan).
Bone marrow aspiration and biopsy.
If cancer is found, the following tests may be done to study the cancer cells:
Immunohistochemistry.
Cytogenetic analysis.
Immunophenotyping.
Other tests and procedures may be done depending on the signs and symptoms seen and where the cancer forms in the body.[12][13]
Causes
The many different forms of lymphoma probably have different causes. These possible causes and associations with at least some forms of NHL include:
Familial lymphoid cancer is rare. The familial risk of lymphoma is elevated for multiple lymphoma subtypes, suggesting a shared genetic cause. However, a family history of a specific subtype is most strongly associated with risk for that subtype, indicating that these genetic factors are subtype-specific. Genome-wide association studies have successfully identified 67 single-nucleotide polymorphisms from 41 loci, most of which are subtype specific.[26]
HIV/AIDS
The Centers for Disease Control and Prevention (CDC) included certain types of non-Hodgkin lymphoma as AIDS-defining cancers in 1987.[27] Immune suppression rather than HIV itself is implicated in the pathogenesis of this malignancy, with a clear correlation between the degree of immune suppression and the risk of developing NHL. Additionally, other retroviruses, such as HTLV, may be spread by the same mechanisms that spread HIV, leading to an increased rate of co-infection.[28] The natural history of HIV infection has greatly changed over time. As a consequence, rates of non-Hodgkin lymphoma (NHL) in people infected with HIV has significantly declined in recent years.[16]
The most common chemotherapy used for B-cell non-Hodgkin lymphoma is R-CHOP, which is a regimen of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab.[32]
R-CHP with polatuzumab vedotin, an antibody-drug conjugate, was included as a category 1 preferred regimen for first-line DLBCL by the National Comprehensive Cancer Network in 2023.[33]
Treatment complications
If participants receive stem-cell transplants, they can develop a graft-versus-host disease. When compared with placebo for treating immune mediated inflammation post transplantation and in autoimmunity, mesenchymal stromal cells (MSCs) may reduce the all-cause mortality if they are used for a therapeutic reason.[34] Moreover, the therapeutic use of MSCs may increase the complete response of acute and chronic GvHD, but the evidence is very uncertain.[34] The evidence suggests that MSCs for prophylactic reason result in little to no difference in the all-cause mortality, in the relapse of malignant diseases, and in the incidence of acute GvHD.[34] The evidence suggests that MSCs for prophylactic reason reduce the incidence of chronic GvHD.[34]
Platelet transfusions may be necessary for those who receive chemotherapy or undergo a stem cell transplantation due to the higher risk for bleeding. When comparing therapeutic/non-prophylactic platelet transfusions to prophylactic platelet transfusions there is little to no difference in the mortality secondary to bleeding and they may result in a slight reduction in the number of days on which a significant bleeding event occurred.[35] The evidence suggests that therapeutic platelet transfusions result in a large increase in the number of people with at least one significant bleeding event and they likely result in a large reduction in the number of platelet transfusions.[35][36]
Other
It is unclear if including aerobic physical exercise, in addition to the standard treatment for adult patients with haematological malignancies, is effective at reducing anxiety and serious adverse effects.[37] Aerobic physical exercises may result in little to no difference in the mortality, in the quality of life and in the physical functioning.[37] These exercises may result in a slight reduction in depression and most likely reduce fatigue.[37]
Prognosis
Prognosis depends on the subtype, the staging, a person's age, and other factors. Across all subtypes, 5-year survival for NHL is 71-74%.[38][39][40]
Epidemiology
Globally, as of 2010, there were 210,000 deaths, up from 143,000 in 1990.[41]
Rates of non-Hodgkin lymphoma increase steadily with age.[20] Up to 45 years NHL is more common among males than females.[42]
Australia
Around 6600 people are diagnosed with non-Hodgkin lymphoma in Australia each year.[43]
Canada
In Canada NHL is the fifth most common cancer in males and sixth most common cancer in females. The lifetime probability of developing a lymphoid cancer is 1 in 44 for males, and 1 in 51 for females.[44]
United Kingdom
On average, according to data for the 2014–2016 period, around 13,900 people are diagnosed with NHL yearly. It is the sixth most common cancer in the UK, and is the eleventh most common cause of cancer death accounting for around 4,900 deaths per year.[45]
United States
Age adjusted data from 2012 to 2016 shows about 19.6 cases of NHL per 100,000 adults per year, 5.6 deaths per 100,000 adults per year, and around 694,704 people living with non-Hodgkin lymphoma. About 2.2 percent of men and women will be diagnosed with NHL at some point during their lifetime.[46]
The American Cancer Society lists non-Hodgkin lymphoma as one of the most common cancers in the United States, accounting for about 4% of all cancers.[47]
History
While consensus was rapidly reached on the classification of Hodgkin lymphoma, there remained a large group of very different diseases requiring further classification. The Rappaport classification, proposed by Henry Rappaport in 1956 and 1966, became the first widely accepted classification of lymphomas other than Hodgkin. Following its publication in 1982, the Working Formulation became the standard classification for this group of diseases. It introduced the term non-Hodgkin lymphoma or NHL and defined three grades of lymphoma.[citation needed]
NHL consists of many different conditions that have little in common with each other. They are grouped by their aggressiveness. Less aggressive non-Hodgkin lymphomas are compatible with a long survival while more aggressive non-Hodgkin lymphomas can be rapidly fatal without treatment. Without further narrowing, the label is of limited usefulness for people or doctors. The subtypes of lymphoma are listed there.[citation needed]
Nevertheless the Working Formulation and the NHL category continue to be used by many. To this day, lymphoma statistics are compiled as Hodgkin's versus non-Hodgkin lymphomas by major cancer agencies, including the US National Cancer Institute in its SEER program, the Canadian Cancer Society and the IARC.[citation needed]
^Audebert A (April 2005). "[Women with endometriosis: are they different from others?]". Gynécologie, Obstétrique & Fertilité (in French). 33 (4): 239–46. doi:10.1016/j.gyobfe.2005.03.010. PMID15894210.
^Somigliana E, Vigano' P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P (May 2006). "Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence". Gynecologic Oncology. 101 (2): 331–41. doi:10.1016/j.ygyno.2005.11.033. PMID16473398.
^Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, Aoki S, Minami M, Uozaki H, Fukayama M, Ohtomo K (2009). "Spectrum of Epstein-Barr virus-related diseases: A pictorial review". Japanese Journal of Radiology. 27 (1): 4–19. doi:10.1007/s11604-008-0291-2. PMID19373526. S2CID6970917.
^ abPinzone MR, Fiorica F, Di Rosa M, Malaguarnera G, Malaguarnera L, Cacopardo B, Zanghì G, Nunnari G (October 2012). "Non-AIDS-defining cancers among HIV-infected people". European Review for Medical and Pharmacological Sciences. 16 (10): 1377–88. PMID23104654.
^ abTobias J, Hochhauser D (2015). Cancer and its Management (7th ed.). Wiley-Blackwell. ISBN978-1-118-46871-5.
^Arnold S Freedman, Lee M Nadler (2000). "Chapter 130: Non–Hodgkin's Lymphomas". In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E III (eds.). Holland-Frei Cancer Medicine (5th ed.). Hamilton, Ont: B.C. Decker. ISBN1-55009-113-1. Archived from the original on 10 September 2017.
^ abEstcourt L, Stanworth S, Doree C, Hopewell S, Murphy MF, Tinmouth A, Heddle N, et al. (Cochrane Haematological Malignancies Group) (May 2012). "Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation". The Cochrane Database of Systematic Reviews (5): CD004269. doi:10.1002/14651858.CD004269.pub3. PMID22592695.
^Patte C, Bleyer A, Cairo MS (2007). "Non-Hodgkin Lymphoma". In Bleyer WA, Barr RD (eds.). Cancer in Adolescents and Young Adults (Pediatric Oncology). Springer. p. 129. doi:10.1007/978-3-540-68152-6_9. ISBN978-3-540-40842-0.
